Venanprubart

DB18891InvestigationalProtein Based Therapies

Venanprubart is under investigation in clinical trial NCT05781451 (Anti-btla Agonist Therapy in Subjects With Primary Sjogren's Syndrome).

Mechanism: Pharmacologically active on B- and T-lymphocyte attenuator
Curator reviewed
Code names: LY3361237

Resolves to

Compound

Targets

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Venanprubart, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.